ConductScience.org, home

Paper · 32053675

References34

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
119692680Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.N Engl J Med2009https://conductscience.org/library/papers/19692680PubMed
228494184Current status of research and treatment for non-small cell lung cancer in never-smoking females.Cancer Biol Ther2017https://conductscience.org/library/papers/28494184PubMed
316818686Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.Clin Cancer Res2006https://conductscience.org/library/papers/16818686PubMed
424419411A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).J Thorac Oncol2014https://conductscience.org/library/papers/24419411PubMed
524908327Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis.J Cancer Res Clin Oncol2014https://conductscience.org/library/papers/24908327PubMed
627908825EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients.J Thorac Oncol2017https://conductscience.org/library/papers/27908825PubMed
731384460Association between EGFR exon 19 or exon 21 mutations and survival rates after first-line EGFR-TKI treatment in patients with non-small cell lung cancer.Mol Clin Oncol2019https://conductscience.org/library/papers/31384460PubMed
824002608EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice.Br J Cancer2013https://conductscience.org/library/papers/24002608PubMed
921841502Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.J Thorac Oncol2011https://conductscience.org/library/papers/21841502PubMed
1025668120Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations.J Thorac Oncol2015https://conductscience.org/library/papers/25668120PubMed
1123558737The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study.BMJ Open2013https://conductscience.org/library/papers/23558737PubMed
127521815Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature.Chest1994https://conductscience.org/library/papers/7521815PubMed
1325897154
Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.
J Clin Oncol2015https://conductscience.org/library/papers/25897154PubMed
1416467097Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.Clin Cancer Res2006https://conductscience.org/library/papers/16467097PubMed
1528599445Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations.Oncol Lett2017https://conductscience.org/library/papers/28599445PubMed
1617167137Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.N Engl J Med2006https://conductscience.org/library/papers/17167137PubMed
1725558790The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer.Lung Cancer2015https://conductscience.org/library/papers/25558790PubMed
1824285021Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.Ann Oncol2014https://conductscience.org/library/papers/24285021PubMed
1918403609EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression.J Mol Diagn2008https://conductscience.org/library/papers/18403609PubMed
2020573926Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.N Engl J Med2010https://conductscience.org/library/papers/20573926PubMed

papers-2026-11-12-0.1.0

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/papers/v1/32053675/references